Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review

被引:15
作者
Xie, Wang [1 ]
Hu, NaNa [1 ]
Cao, LeJie [1 ]
机构
[1] Univ Sci & Technol China, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Div Life Sci & Med, Hefei, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
中国国家自然科学基金;
关键词
programmed cell death 1 inhibitor; immune thrombocytopenia; immune checkpoint inhibitor; atezolizumab; immune-related adverse event (irAE); ADVERSE EVENTS; NIVOLUMAB; PATIENT; PEMBROLIZUMAB;
D O I
10.3389/fimmu.2021.790051
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immune checkpoint inhibitors (ICIs), including antibodies targeting programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1), are being extensively used on advanced human malignancies therapy. The treatment with ICIs have acquired durable tumor inhibition and changed the treatment landscape in lung cancer. Immune-related adverse events including pneumonitis and thyroiditis have been well described, but less frequent events, such as ICIs-induced thrombocytopenia, are now emerging and may sometimes be severe or fatal. Since early detection and prompt intervention are crucial to prevent fatal consequences, it is of outmost importance that medical staff is aware of these potential toxicities and learn to recognize and treat them adequately. This review focuses on the epidemiology, clinical presentation, mechanisms, and clinical management of ICIs-induced thrombocytopenia in patients with lung cancer. We also present a patient with advanced lung adenocarcinoma who received the PD-L1 inhibitor atezolizumab and eventually developed severe thrombocytopenia. The case indirectly suggests that cytokine changes might contribute to immune dysregulation in ICIs-induced thrombocytopenia.
引用
收藏
页数:6
相关论文
共 39 条
  • [1] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
    Abdayem, Pamela
    Planchard, David
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
  • [2] Immune thrombocytopenia after immune checkpoint inhibitor therapy
    Amanam, Idoroenyi
    Gupta, Rohan
    Pullarkat, Vinod
    Mei, Matthew
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 677 - 681
  • [3] Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy
    Assi, Hussein A.
    Asch, Adam S.
    Machiorlatti, Michael
    Vesely, Sara K.
    Ibrahimi, Sami
    [J]. FUTURE SCIENCE OA, 2020, 6 (07):
  • [4] Bagley S.J., 2016, Cancer Treat. Commun, V6, P20, DOI DOI 10.1016/J.CTRC.2016.02.009
  • [5] Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system
    Bai, Shuai
    Tian, Tiantian
    Pacheco, Jose M.
    Tachihara, Motoko
    Hu, Pingping
    Zhang, Jiandong
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2614 - +
  • [6] A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia
    Berger, Mathilde
    Amini-Adle, Mona
    Crumbach, Laura
    Paubelle, Etienne
    Dalle, Stephane
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 112 : 94 - 97
  • [7] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [8] Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma
    Bulbul, A.
    Mustafa, A.
    Chouial, S.
    Rashad, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (07) : 1675 - 1676
  • [9] Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
    Calvo, Roser
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [10] Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
    Cortellini, Alessio
    Chiari, Rita
    Ricciuti, Biagio
    Metro, Giulio
    Perrone, Fabiana
    Tiseo, Marcello
    Bersanelli, Melissa
    Bordi, Paola
    Santini, Daniele
    Giusti, Raffaele
    Grassadonia, Antonino
    Di Marino, Pietro
    Tinari, Nicola
    De Tursi, Michele
    Zoratto, Federica
    Veltri, Enzo
    Malorgio, Francesco
    Garufi, Carlo
    Russano, Marco
    Anesi, Cecilia
    Zeppola, Tea
    Filetti, Marco
    Marchetti, Paolo
    Berardi, Rossana
    Rinaldi, Silvia
    Tudini, Marianna
    Silva, Rosa Rita
    Pireddu, Annagrazia
    Atzori, Francesco
    Iacono, Daniela
    Migliorino, Maria Rita
    Porzio, Gampiero
    Cannita, Katia
    Ficorella, Corrado
    Buti, Sebastiano
    [J]. CLINICAL LUNG CANCER, 2019, 20 (04) : 237 - +